Reset filter
Nyckelord
Schizofrene stoornissen ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Klinisk studie
  2. 2. Rutindokumentation
  3. 3. Register- och kohortstudier
  4. 4. Kvalitetssäkring
  5. 5. Datastandard
  6. 6. Frågeformulär för patienter
  7. 7. Medicinsk specialitet
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

383 Sökresultat.
Relevans Bedömning Nya först Gamla först

Eligibility Schizophrenia NCT01810783

- 2020-11-24 - 1 Formulär, 2 Item-grupper, 8 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Brexpiprazole in Patients With Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01810783 according to the information on www.clinicaltrials.gov other inclusion and exclusion criteria may apply.

Eligibility Schizophrenia NCT01879709

- 2020-09-28 - 1 Formulär, 2 Item-grupper, 10 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Yoga as Cognitive Remediation in Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01879709

Measurement Instrument Database for the Social Science (MIDSS) - The Perceived Family Burden Scale (PFBS)

- 2020-07-20 - 1 Formulär, 1 Item-grupp, 49 Dataelement, 1 Språk
Item-grupp: THE PERCEIVED FAMILY BURDEN SCALE
Levene, J. E., Lancee, W. J., Seeman, M. V. (1996). The Perceived Family Burden Scale (PFBS). Measurement Instrument Database for the Social Science. Retrieved 20.07.2020, from www.midss.ie Key references: Levene, J. E., Lancee, W. J., Seeman, M. V. (1996). The perceived family burden scale: measurement and validation. Schizophrenia Research, 22(2), 151–157. Primary use / Purpose: The Perceived Family Burden Scale (PFBS) is a 24-item questionnaire rated on a 5 point Likert type scale. It contains an additional choice for each of the items where the user can also identify that the particular symptom is not present. The purpose of the scale is to measure the burden of schizophrenia on the family of a patient. Background: Many scales have been developed for the classification of, and quality of life associated with, mental illness. However, less attention has been paid to the families of mentally ill patients who can also experience difficulty. Many family members in this situation have to take on fulltime roles as caregivers, or at the very least experience they a heightened concern for the well-being of the patient and themselves. To measure this possible burden in relation to schizophrenia, in particular, the Perceived Family Burden Scale (PFBS) was developed. Psychometrics: The psychometric properties of the Perceived Family Burden Scale (PFBS) are discussed in Levene, Lancee, & Seeman, (1996). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.399 INSTRUCTIONS FOR RATERS The Perceived Family Burden Scale is rated on a five point scale, with a range from 0 to 5. Ratings: 0 = the behaviour isn’t present and doesn’t bother the relative 1 = the behaviour is present and doesn’t bother the relative 2 = the behaviour is present and bothers the relative “a little”. 3 = the behaviour is present and bothers the relative “considerably”. 4 = the behaviour is present and bothers the relative “a great deal”. In our study, we derived three variables which were used in the validation study: 1) the total score 2) an “objective score” (the number of problem behaviours identified by the informant). 3) a “subjective score” (the extent to which the behaviour “bothers” the relative).

Eligibility Schizophrenia NCT02086162

- 2020-04-19 - 1 Formulär, 2 Item-grupper, 11 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Randomized Controlled Trial (RCT) of a Motivational Decision Support System; ODM derived from: https://clinicaltrials.gov/show/NCT02086162

Eligibility Relapse Schizophrenia NCT01885923

- 2020-03-05 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
A RCT Study in Schizophrenia Relapse Prevention; ODM derived from: https://clinicaltrials.gov/show/NCT01885923

Eligibility Schizophrenia NCT01685931

- 2019-12-31 - 1 Formulär, 2 Item-grupper, 9 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics; ODM derived from: https://clinicaltrials.gov/show/NCT01685931

Eligibility Genetic High Risk for Schizophrenia NCT01943175

- 2019-12-20 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia; ODM derived from: https://clinicaltrials.gov/show/NCT01943175

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Day 1 RE-TEST

- 2019-12-18 - 1 Formulär, 18 Item-grupper, 81 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Allen test, Vital signs, Pulmonary function tests, 12 lead ECG, Holter Electrocardiography, Positron-Emission Tomography, Pre-dose, Pharmacokinetic aspects - Blood, Randomization, Numbers, Therapeutic procedure, Confirmation, Experimental drug, Positron-Emission Tomography, Post-dose, Physical Examination, Post-dose, Vital signs, Post-dose, Laboratory Procedures, Post-dose, Hematology finding, Laboratory Procedures, Post-dose, Chemistry, Clinical, Urinalysis, Post-dose, Laboratory Procedures, Post-dose, Renal function
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Investigator's Signature

- 2019-12-18 - 1 Formulär, 2 Item-grupper, 4 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Investigator Signature
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Investigator Comment Log

- 2019-12-18 - 1 Formulär, 2 Item-grupper, 3 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Clinical Investigators, Comment
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Study Conclusion

- 2019-12-18 - 1 Formulär, 2 Item-grupper, 6 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Clinical Trials, Conclusion
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Brain Penetration by [Carbonyl-11C] GSK1034702; 110771 - Serious Adverse Event (SAE)

- 2019-12-18 - 1 Formulär, 13 Item-grupper, 44 Dataelement, 1 Språk
Item-grupper: Administrative documentation, Serious Adverse Event, Serious Adverse Event, Seriousness of Adverse Event, Serious Adverse Event, Demography, Serious Adverse Event, Relationships, Experimental drug, Serious Adverse Event, Etiology aspects, Serious Adverse Event, Disease, Serious Adverse Event, Risk factors, Serious Adverse Event, Concomitant Agent, Serious Adverse Event, Experimental drug, Details, Serious Adverse Event, Diagnostic Procedure, Serious Adverse Event, Comment, Serious Adverse Event, Investigator Signature
Study ID: 110771 Clinical Study ID: 110771 Study Title: An open label positron emission tomography (PET) study to investigate brain penetration by [carbonyl-11C] GSK1034702 in healthy subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Positron Emission Tomography Trade Name: Carbonyl-11C Study Indication: Cognitive Disorders, Alzheimer's disease, schizophrenia.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial